Abstract
Bone Morphogenetic Proteins (BMPs), members of the TGF-β superfamily, are pleiotropic growth factors, known for their role in embryogenesis and bone induction. BMPs signal via two types of serine/threonine kinase BMP receptors (BMPRs), type I, and type II receptors. Ligand binding induces activation of the downstream signalling molecules, the SMADs, which regulate the expression of BMP-responsive genes including those involved in processes such as differentiation, proliferation and apoptosis. BMP signalling is coordinated by both extrinsic and intrinsic mechanisms in order to ensure the control of these important processes. Irregularities however, can occur at any step during the downstream BMP pathway, and aberrations have been implicated in the pathogenesis of several tumour types including: prostate, colorectal, osteosarcomas, myelomas and breast cancer, amongst others. As so many signalling molecules take part in the BMP network, the specific role that these characters play in the pathogenesis of these tumours is rather complex, and hence unclear. In this review, we summarise and consider current literature on BMP signalling, its regulation, and any aberrations in the pathway, focusing on the role of BMPRs, and SMADs on the development, progression and metastasis of solid tumours.
Keywords: Bone morphogenetic protein, signalling, cancer, BMP Receptor, SMAD
Current Signal Transduction Therapy
Title: When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Volume: 4 Issue: 3
Author(s): Sivan Mili Bokobza, Lin Ye and Wen Guo Jiang
Affiliation:
Keywords: Bone morphogenetic protein, signalling, cancer, BMP Receptor, SMAD
Abstract: Bone Morphogenetic Proteins (BMPs), members of the TGF-β superfamily, are pleiotropic growth factors, known for their role in embryogenesis and bone induction. BMPs signal via two types of serine/threonine kinase BMP receptors (BMPRs), type I, and type II receptors. Ligand binding induces activation of the downstream signalling molecules, the SMADs, which regulate the expression of BMP-responsive genes including those involved in processes such as differentiation, proliferation and apoptosis. BMP signalling is coordinated by both extrinsic and intrinsic mechanisms in order to ensure the control of these important processes. Irregularities however, can occur at any step during the downstream BMP pathway, and aberrations have been implicated in the pathogenesis of several tumour types including: prostate, colorectal, osteosarcomas, myelomas and breast cancer, amongst others. As so many signalling molecules take part in the BMP network, the specific role that these characters play in the pathogenesis of these tumours is rather complex, and hence unclear. In this review, we summarise and consider current literature on BMP signalling, its regulation, and any aberrations in the pathway, focusing on the role of BMPRs, and SMADs on the development, progression and metastasis of solid tumours.
Export Options
About this article
Cite this article as:
Bokobza Mili Sivan, Ye Lin and Jiang Guo Wen, When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer, Current Signal Transduction Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157436209789057485
DOI https://dx.doi.org/10.2174/157436209789057485 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Recent Patents on Anti-Cancer Drug Discovery Oncogenic miR-544 is an Important Molecular Target in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Focus on MicroRNAs as Biomarker in Pediatric Diseases
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Betulin-Betulinic Acid Natural Product Based Analogs as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Segmentation and Classification of Lung Cancer: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nanotechnology Enabled Drug Delivery Systems for Bone and Cartilage Regeneration
Recent Patents on Biomedical Engineering (Discontinued) Quercetin and MicroRNA Interplay in Apoptosis Regulation in Ovarian Cancer
Current Pharmaceutical Design Effect of Oil Extract from Microalgae (<i>Schizochytrium</i> sp.) on the Viability and Apoptosis of Human Osteosarcoma Cells
Current Pharmaceutical Biotechnology LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Structure-Function Relationships of PEDF
Current Molecular Medicine Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Quinones Derived from Plant Secondary Metabolites as Anti-cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Apoptotic Effects of N-(2-Hydroxyphenyl)-2-Propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties
Anti-Cancer Agents in Medicinal Chemistry E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design